Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3
- Registration Number
- NCT04052204
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇧🇪GZA Ziekenhuizen campus Sint-Augustinus, Wilrijk, Antwerpen, Belgium
Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 19
- Registration Number
- NCT04004442
- Locations
- 🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03990571
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Hope Rugo, MD
- Target Recruit Count
- 150
- Registration Number
- NCT03971409
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-29
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- P. C. Thuss-Patience
- Target Recruit Count
- 59
- Registration Number
- NCT03966118
- Locations
- 🇩🇪
Charité Universitätsmedizin Berlin, Berlin, Germany
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 24
- Registration Number
- NCT03964532
- Locations
- 🇺🇸
University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Institut Paoli-Calmettes
- Target Recruit Count
- 67
- Registration Number
- NCT03950362
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 60
- Registration Number
- NCT03944941
- Locations
- 🇺🇸
Mount Carmel East Hospital, Columbus, Ohio, United States
🇺🇸Oncology Hematology Association, Pittsburgh, Pennsylvania, United States
🇺🇸UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania, United States
Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 54
- Registration Number
- NCT03944252
- Locations
- 🇮🇹
Istituto Oncologico Veneto IRCCS, Padova, Italy
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03941262
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.